Drug intelligence / Profile preview

ibogaine + magnesium

Development stage
Unknown
Lead developer
Ambio Life Sciences
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral, Intravenous
01

Overview

Ibogaine + magnesium is a combination therapy consisting of the plant-derived psychoactive compound ibogaine and the mineral magnesium. Ibogaine is classified as an atypical psychedelic or oneirogen and acts on multiple neurotransmitter systems, including serotonin, dopamine, and glutamate pathways. It has been primarily studied for its potential in treating substance use disorders but has also shown promise in alleviating neuropsychiatric symptoms such as PTSD, depression, anxiety, and functional disability associated with traumatic brain injury (TBI). Magnesium is co-administered to mitigate ibogaine’s known risk of cardiac arrhythmias (notably QT prolongation), enhancing safety during treatment. The combination was evaluated in a prospective observational study (the MISTIC protocol) involving veterans with TBI and severe psychiatric symptoms. Results indicated significant improvements in functioning and reductions in PTSD, depression, and anxiety scores at one month post-treatment without serious adverse events[1][5][6][7]. Controlled clinical trials are needed to confirm efficacy.

Other names
magnesium-ibogainemagnesium–ibogaine therapyMISTIC protocol
02

Targets

DAT (Dopamine plasma membrane transport protein)NMDAR (Glutamate receptor ionotropic, NMDA)SERT (Sodium-dependent serotonin transporter)TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))KCNH2 (Voltage-gated potassium channel subfamily H member 2)

Beyond the preview

Go deeper on ibogaine + magnesium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibogaine + magnesium.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call